BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
14
08
2018
revised:
15
02
2019
accepted:
30
04
2019
pubmed:
23
5
2019
medline:
10
9
2020
entrez:
23
5
2019
Statut:
ppublish
Résumé
We present a case of a patient with multiply relapsed, refractory myeloma whose clinical course showed evidence of a synergistic abscopal-like response to chimeric antigen receptor (CAR) T-cell therapy and localized radiotherapy (XRT). Shortly after receiving B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy, the patient required urgent high-dose steroids and XRT for spinal cord compression. Despite the steroids, the patient had a durable systemic response that could not be attributed to XRT alone. Post-XRT findings included a second wave of fever and increased CRP and IL6, beginning 21 days after CAR T cells, which is late for cytokine-release syndrome from CAR T-cell therapy alone on this trial. Given this response, which resembled cytokine-release syndrome, immediately following XRT, we investigated changes in the patient's T-cell receptor (TCR) repertoire over 10 serial time points. Comparing T-cell diversity via Morisita's overlap indices (
Identifiants
pubmed: 31113804
pii: 2326-6066.CIR-18-0551
doi: 10.1158/2326-6066.CIR-18-0551
pmc: PMC6606365
mid: NIHMS1528833
doi:
Substances chimiques
B-Cell Maturation Antigen
0
Receptors, Antigen, T-Cell
0
TNFRSF17 protein, human
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1053Subventions
Organisme : NIH HHS
ID : U54 OD020355
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA138738
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA190174
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA059350
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Cancer Immunol Res. 2013 Dec;1(6):365-72
pubmed: 24563870
Oncoimmunology. 2014 May 14;3:e28780
pubmed: 25083318
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Br J Cancer. 2016 Jul 12;115(2):252-60
pubmed: 27380136
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
N Engl J Med. 2017 Aug 24;377(8):783-784
pubmed: 28834486
Clin Cancer Res. 2018 Feb 15;24(4):882-895
pubmed: 29162646
Cancer Res. 2018 Feb 15;78(4):1031-1043
pubmed: 29222400
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Mol Ther. 2018 Jun 6;26(6):1447-1456
pubmed: 29678657
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
Mol Ther. 2018 Nov 7;26(11):2542-2552
pubmed: 30415658